{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:51:49Z","timestamp":1795060309311,"version":"4.10.2"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clearance of neurotoxic brain proteins via cerebrospinal fluid (CSF) to blood has recently emerged to be crucial, and plasma biomarkers of neurodegeneration were newly introduced to predict neurological disease. This study examines in 106 individuals with neurological disorders associations between plasma biomarkers [40 and 42 amino acid-long amyloid-\u03b2 (A\u03b240 and A\u03b242), total-tau, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL)] and magnetic resonance imaging measures of CSF-mediated clearance from brain via extra-vascular pathways (proxy of glymphatic function) and CSF-to-blood clearance variables from pharmacokinetic modeling (proxy of meningeal lymphatic egress). We also examine how biomarkers vary during daytime and associate with subjective sleep quality. Plasma concentrations of neurodegeneration markers associate with indices of glymphatic and meningeal lymphatic functions in individual- and disease-specific manners, vary during daytime, but are unaffected by sleep quality. The results suggest that plasma concentrations of neurodegeneration biomarkers associate with measures of glymphatic and meningeal lymphatic function.<\/jats:p>","DOI":"10.1038\/s41467-023-37685-5","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:03:25Z","timestamp":1681297405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6881-9280","authenticated-orcid":false,"given":"Per Kristian","family":"Eide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslan","family":"Lashkarivand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Are","family":"Pripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Magnus","family":"Valnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-0934","authenticated-orcid":false,"given":"Markus Herberg","family":"Hovd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0919-4510","authenticated-orcid":false,"given":"Geir","family":"Ringstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"37685_CR1","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters, C. L. et al. Alzheimer\u2019s disease. Nat. Rev. Dis. Prim. 1, 15056 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"37685_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway, J. M. et al. Clearance systems in the brain-implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457\u2013470 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"37685_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.abi5208","volume":"373","author":"K Blennow","year":"2021","unstructured":"Blennow, K. Phenotyping Alzheimer\u2019s disease with blood tests. Science 373, 626\u2013628 (2021).","journal-title":"Science"},{"key":"37685_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"37685_CR5","doi-asserted-by":"publisher","first-page":"147ra111","DOI":"10.1126\/scitranslmed.3003748","volume":"4","author":"JJ Iliff","year":"2012","unstructured":"Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl. Med. 4, 147ra111 (2012).","journal-title":"Sci. Transl. Med."},{"key":"37685_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337\u2013341 (2015).","journal-title":"Nature"},{"key":"37685_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1084\/jem.20142290","volume":"212","author":"A Aspelund","year":"2015","unstructured":"Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991\u2013999 (2015).","journal-title":"J. Exp. Med."},{"key":"37685_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41586-021-03489-0","volume":"593","author":"S Da Mesquita","year":"2021","unstructured":"Da Mesquita, S. et al. Meningeal lymphatics affect microglia responses and anti-A\u03b2 immunotherapy. Nature 593, 255\u2013260 (2021).","journal-title":"Nature"},{"key":"37685_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18115-2","volume":"11","author":"LM Hablitz","year":"2020","unstructured":"Hablitz, L. M. et al. Circadian control of brain glymphatic and lymphatic fluid flow. Nat. Commun. 11, 4411 (2020).","journal-title":"Nat. Commun."},{"key":"37685_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1241224","volume":"342","author":"L Xie","year":"2013","unstructured":"Xie, L. et al. Sleep drives metabolite clearance from the adult brain. Science 342, 373\u2013377 (2013).","journal-title":"Science"},{"key":"37685_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00401-018-1916-x","volume":"137","author":"Q Ma","year":"2019","unstructured":"Ma, Q. et al. Rapid lymphatic efflux limits cerebrospinal fluid flow to the brain. Acta Neuropathol. 137, 151\u2013165 (2019).","journal-title":"Acta Neuropathol."},{"key":"37685_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.121537","volume":"3","author":"G Ringstad","year":"2018","unstructured":"Ringstad, G. et al. Brain-wide glymphatic enhancement and clearance in humans assessed with MRI. JCI Insight 3, 1\u201316 (2018).","journal-title":"JCI Insight"},{"key":"37685_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.147063","volume":"6","author":"PK Eide","year":"2021","unstructured":"Eide, P. K. et al. Clinical application of intrathecal gadobutrol for assessment of cerebrospinal fluid tracer clearance to blood. JCI Insight 6, 1\u201313 (2021).","journal-title":"JCI Insight"},{"key":"37685_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-022-00352-w","volume":"19","author":"MH Hovd","year":"2022","unstructured":"Hovd, M. H. et al. Population pharmacokinetic modeling of CSF to blood clearance: prospective tracer study of 161 patients under work-up for CSF disorders. Fluids Barriers CNS 19, 55 (2022).","journal-title":"Fluids Barriers CNS"},{"key":"37685_CR15","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1172\/JCI90603","volume":"127","author":"A Louveau","year":"2017","unstructured":"Louveau, A. et al. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J. Clin. Invest. 127, 3210\u20133219 (2017).","journal-title":"J. Clin. Invest."},{"key":"37685_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14195-x","volume":"11","author":"G Ringstad","year":"2020","unstructured":"Ringstad, G. & Eide, P. K. Cerebrospinal fluid tracer efflux to parasagittal dura in humans. Nat. Commun. 11, 354 (2020).","journal-title":"Nat. Commun."},{"key":"37685_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/brain\/awaa443","volume":"144","author":"PK Eide","year":"2021","unstructured":"Eide, P. K., Vinje, V., Pripp, A. H., Mardal, K. A. & Ringstad, G. Sleep deprivation impairs molecular clearance from the human brain. Brain 144, 863\u2013874 (2021).","journal-title":"Brain"},{"key":"37685_CR18","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1177\/0271678X221090747","volume":"42","author":"PK Eide","year":"2022","unstructured":"Eide, P. K. et al. Altered glymphatic enhancement of cerebrospinal fluid tracer in individuals with chronic poor sleep quality. J. Cereb. Blood Flow. Metab. 42, 1676\u20131692 (2022).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"37685_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2176\/nmc.52.775","volume":"52","author":"E Mori","year":"2012","unstructured":"Mori, E. et al. Guidelines for management of idiopathic normal pressure hydrocephalus: second edition. Neurol. Med. Chir. 52, 775\u2013809 (2012).","journal-title":"Neurol. Med. Chir."},{"key":"37685_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3233\/JAD-160542","volume":"55","author":"WA Banks","year":"2017","unstructured":"Banks, W. A. et al. Tau proteins cross the blood-brain barrier. J. Alzheimer\u2019s Dis. 55, 411\u2013419 (2017).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"37685_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson, O., Lehmann, S., Otto, M., Zetterberg, H. & Lewczuk, P. Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease. Alzheimer\u2019s Res. Ther. 11, 34 (2019).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"37685_CR22","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"37685_CR23","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","volume":"98","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques. Neurology 98, e688\u2013e699 (2022).","journal-title":"Neurology"},{"key":"37685_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-022-00318-y","volume":"19","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Decreased CSF clearance and increased brain amyloid in Alzheimer\u2019s disease. Fluids Barriers CNS 19, 21 (2022).","journal-title":"Fluids Barriers CNS"},{"key":"37685_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/joim.13332","volume":"290","author":"DOT Alawode","year":"2021","unstructured":"Alawode, D. O. T. et al. Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer\u2019s disease. J. Intern. Med. 290, 583\u2013601 (2021).","journal-title":"J. Intern. Med."},{"key":"37685_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy, S. et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer\u2019s Res. Ther. 13, 198 (2021).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"37685_CR27","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy, A. et al. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol. Med. 14, e14408 (2022).","journal-title":"EMBO Mol. Med."},{"key":"37685_CR28","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"37685_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak, A. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 18, 158\u2013172 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"37685_CR30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471\u20131483 (2021).","journal-title":"JAMA Neurol."},{"key":"37685_CR31","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira, J. B. et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144, 3505\u20133516 (2021).","journal-title":"Brain"},{"key":"37685_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035\u20131048 (2019).","journal-title":"JAMA Neurol."},{"key":"37685_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/00365513.2020.1730434","volume":"80","author":"CVB Hviid","year":"2020","unstructured":"Hviid, C. V. B., Knudsen, C. S. & Parkner, T. Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scand. J. Clin. Lab. Invest. 80, 291\u2013295 (2020).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"37685_CR34","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870\u2013881 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"37685_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat. Med. 25, 277\u2013283 (2019).","journal-title":"Nat. Med."},{"key":"37685_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/alz.12385","volume":"18","author":"DW Nauen","year":"2022","unstructured":"Nauen, D. W. & Troncoso, J. C. Amyloid-beta is present in human lymph nodes and greatly enriched in those of the cervical region. Alzheimer\u2019s Dement. 18, 205\u2013210 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"37685_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0312-x","volume":"14","author":"TK Patel","year":"2019","unstructured":"Patel, T. K. et al. Dural lymphatics regulate clearance of extracellular tau from the CNS. Mol. Neurodegener. 14, 11 (2019).","journal-title":"Mol. Neurodegener."},{"key":"37685_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133\u2013150 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"37685_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2019.146547","volume":"1727","author":"PK Eide","year":"2020","unstructured":"Eide, P. K. & Hansson, H.-A. Blood-brain barrier leakage of blood proteins in idiopathic normal pressure hydrocephalus. Brain Res. 1727, 1\u201313 (2020).","journal-title":"Brain Res."},{"key":"37685_CR40","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnen\/nlz063","volume":"78","author":"MM Hasan-Olive","year":"2019","unstructured":"Hasan-Olive, M. M., Hansson, H. A., Enger, R., Nagelhus, E. A. & Eide, P. K. Blood-brain barrier dysfunction in idiopathic intracranial hypertension. J. Neuropathol. Exp. Neurol. 78, 808\u2013818 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"37685_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-021-00282-z","volume":"19","author":"SB Hladky","year":"2022","unstructured":"Hladky, S. B. & Barrand, M. A. The glymphatic hypothesis: the theory and the evidence. Fluids Barriers CNS 19, 9 (2022).","journal-title":"Fluids Barriers CNS"},{"key":"37685_CR42","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1152\/physrev.00031.2020","volume":"102","author":"MK Rasmussen","year":"2022","unstructured":"Rasmussen, M. K., Mestre, H. & Nedergaard, M. Fluid transport in the brain. Physiol. Rev. 102, 1025\u20131151 (2022).","journal-title":"Physiol. Rev."},{"key":"37685_CR43","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1177\/0271678X21996175","volume":"41","author":"NB B\u00e8chet","year":"2021","unstructured":"B\u00e8chet, N. B., Shanbhag, N. C. & Lundgaard, I. Glymphatic pathways in the gyrencephalic brain. J. Cereb. Blood Flow. Metab. 41, 2264\u20132279 (2021).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"37685_CR44","first-page":"111","volume":"170","author":"ET Zhang","year":"1990","unstructured":"Zhang, E. T., Inman, C. B. & Weller, R. O. Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. J. Anat. 170, 111\u2013123 (1990).","journal-title":"J. Anat."},{"key":"37685_CR45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.adc8810","volume":"379","author":"K M\u00f8llg\u00e5rd","year":"2023","unstructured":"M\u00f8llg\u00e5rd, K. et al. A mesothelium divides the subarachnoid space into functional compartments. Science 379, 84\u201388 (2023).","journal-title":"Science"},{"key":"37685_CR46","first-page":"e12030","volume":"12","author":"A Verma","year":"2020","unstructured":"Verma, A. et al. Intrathecal (99m)Tc-DTPA imaging of molecular passage from lumbar cerebrospinal fluid to brain and periphery in humans. Alzheimers Dement. 12, e12030 (2020).","journal-title":"Alzheimers Dement."},{"key":"37685_CR47","doi-asserted-by":"crossref","unstructured":"Sigurdsson, B. et al. A SPECT-based method for dynamic imaging of the glymphatic system in rats. J. Cereb. Blood Flow Metab. 271678x231156982 (2023).","DOI":"10.1177\/0271678X231156982"},{"key":"37685_CR48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2463\/mrms.mp.2019-0182","volume":"19","author":"S Naganawa","year":"2020","unstructured":"Naganawa, S. et al. Confirmation of age-dependence in the leakage of contrast medium around the cortical veins into cerebrospinal fluid after intravenous administration of gadolinium-based contrast agent. Magn. Reson. Med. Sci. 19, 375\u2013381 (2020).","journal-title":"Magn. Reson. Med. Sci."},{"key":"37685_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S1474-4422(21)00423-3","volume":"21","author":"T Dobrocky","year":"2022","unstructured":"Dobrocky, T. et al. Spontaneous intracranial hypotension: searching for the CSF leak. Lancet Neurol. 21, 369\u2013380 (2022).","journal-title":"Lancet Neurol."},{"key":"37685_CR50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41591-020-01198-1","volume":"27","author":"XB Ding","year":"2021","unstructured":"Ding, X. B. et al. Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson\u2019s disease. Nat. Med. 27, 411\u2013418 (2021).","journal-title":"Nat. Med."},{"key":"37685_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-019-0147-y","volume":"8","author":"W Zou","year":"2019","unstructured":"Zou, W. et al. Blocking meningeal lymphatic drainage aggravates Parkinson\u2019s disease-like pathology in mice overexpressing mutated alpha-synuclein. Transl. Neurodegener. 8, 7 (2019).","journal-title":"Transl. Neurodegener."},{"key":"37685_CR52","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimer\u2019s Dement."},{"key":"37685_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51373-9","volume":"9","author":"Q Ma","year":"2019","unstructured":"Ma, Q. et al. Lymphatic outflow of cerebrospinal fluid is reduced in glioma. Sci. Rep. 9, 14815 (2019).","journal-title":"Sci. Rep."},{"key":"37685_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/0271678X18822921","volume":"40","author":"P Yanev","year":"2020","unstructured":"Yanev, P. et al. Impaired meningeal lymphatic vessel development worsens stroke outcome. J. Cereb. Blood Flow. Metab. 40, 263\u2013275 (2020).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"37685_CR55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41586-018-0368-8","volume":"560","author":"S Da Mesquita","year":"2018","unstructured":"Da Mesquita, S. et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer\u2019s disease. Nature 560, 185\u2013191 (2018).","journal-title":"Nature"},{"key":"37685_CR56","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41586-019-1912-x","volume":"577","author":"E Song","year":"2020","unstructured":"Song, E. et al. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature 577, 689\u2013694 (2020).","journal-title":"Nature"},{"key":"37685_CR57","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/alz.12806","volume":"18","author":"J Simr\u00e9n","year":"2022","unstructured":"Simr\u00e9n, J. et al. Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability. Alzheimer\u2019s Dement. 18, 1988\u20131992 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"37685_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2022.981399","volume":"16","author":"PK Eide","year":"2022","unstructured":"Eide, P. K. Cellular changes at the glia-neuro-vascular interface in definite idiopathic normal pressure hydrocephalus. Front. Cell. Neurosci. 16, 1\u201318 (2022).","journal-title":"Front. Cell. Neurosci."},{"key":"37685_CR59","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ana.22100","volume":"68","author":"V Leinonen","year":"2010","unstructured":"Leinonen, V. et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer\u2019s disease. Ann. Neurol. 68, 446\u2013453 (2010).","journal-title":"Ann. Neurol."},{"key":"37685_CR60","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S1474-4422(03)00487-3","volume":"2","author":"GD Silverberg","year":"2003","unstructured":"Silverberg, G. D., Mayo, M., Saul, T., Rubenstein, E. & McGuire, D. Alzheimer\u2019s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2, 506\u2013511 (2003).","journal-title":"Lancet Neurol."},{"key":"37685_CR61","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/jpm12060935","volume":"12","author":"S Mazzeo","year":"2022","unstructured":"Mazzeo, S. et al. Alzheimer\u2019s disease CSF biomarker profiles in idiopathic normal pressure hydrocephalus. J. Pers. Med. 12, 935 (2022).","journal-title":"J. Pers. Med."},{"key":"37685_CR62","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1177\/0271678X18760974","volume":"39","author":"PK Eide","year":"2019","unstructured":"Eide, P. K. & Ringstad, G. Delayed clearance of cerebrospinal fluid tracer from entorhinal cortex in idiopathic normal pressure hydrocephalus: a glymphatic magnetic resonance imaging study. J. Cereb. Blood Flow. Metab. 39, 1355\u20131368 (2019).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"37685_CR63","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1126\/science.abb8739","volume":"370","author":"M Nedergaard","year":"2020","unstructured":"Nedergaard, M. & Goldman, S. A. Glymphatic failure as a final common pathway to dementia. Science 370, 50\u201356 (2020).","journal-title":"Science"},{"key":"37685_CR64","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00701-022-05154-5","volume":"164","author":"SG Thavarajasingam","year":"2022","unstructured":"Thavarajasingam, S. G. et al. Cerebrospinal fluid and venous biomarkers of shunt-responsive idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis. Acta Neurochir. 164, 1719\u20131746 (2022).","journal-title":"Acta Neurochir."},{"key":"37685_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-022-00306-2","volume":"19","author":"M Braun","year":"2022","unstructured":"Braun, M. et al. Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus. Fluids Barriers CNS 19, 15 (2022).","journal-title":"Fluids Barriers CNS"},{"key":"37685_CR66","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/nan.12420","volume":"44","author":"PK Eide","year":"2018","unstructured":"Eide, P. K. & Hansson, H. A. Astrogliosis and impaired aquaporin-4 and dystrophin systems in idiopathic normal pressure hydrocephalus. Neuropathol. Appl. Neurobiol. 44, 474\u2013490 (2018).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"37685_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/braincomms\/fcab043","volume":"3","author":"PK Eide","year":"2021","unstructured":"Eide, P. K., Pripp, A. H., Ringstad, G. & Valnes, L. M. Impaired glymphatic function in idiopathic intracranial hypertension. Brain Commun. 3, 1\u201314 (2021).","journal-title":"Brain Commun."},{"key":"37685_CR68","doi-asserted-by":"publisher","first-page":"zsaa147","DOI":"10.1093\/sleep\/zsaa147","volume":"44","author":"A Targa","year":"2021","unstructured":"Targa, A. et al. Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer\u2019s disease. Sleep 44, zsaa147 (2021).","journal-title":"Sleep"},{"key":"37685_CR69","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1212\/WNL.0000000000004171","volume":"89","author":"KE Sprecher","year":"2017","unstructured":"Sprecher, K. E. et al. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology 89, 445\u2013453 (2017).","journal-title":"Neurology"},{"key":"37685_CR70","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl, B. FreeSurfer. Neuroimage 62, 774\u2013781 (2012).","journal-title":"Neuroimage"},{"key":"37685_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.smrv.2015.01.009","volume":"25","author":"T Mollayeva","year":"2016","unstructured":"Mollayeva, T. et al. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: a systematic review and meta-analysis. Sleep. Med. Rev. 25, 52\u201373 (2016).","journal-title":"Sleep. Med. Rev."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37685-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37685-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37685-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T12:06:52Z","timestamp":1681301212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37685-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37685"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-37685-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.K.E. and G.R. are shareholders in BrainWideSolutions AS, Oslo, Norway, which is a holder of patent US 11,272,841. K.B. has served as a consultant on advisory boards or on data monitoring committees for Abcam, Axon, BioArctic, Biogen, and JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. H.Z. has served on scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2084"}}